R&D channel feed

Pfiz­er's JAK in­hibitor clears sec­ond piv­otal eczema study, but can it top­ple Re­gen­eron's Dupix­ent?

6 years ago
Pharma

Led by BioN­Tech, six biotechs line up for Oc­to­ber IPOs

6 years ago

Darza­lex from J&J, Gen­mab scores FDA ap­proval in front­line mul­ti­ple myelo­ma use as Sanofi ri­val looms

6 years ago
Pharma

Biotechs are spend­ing record sums on R&D — should that wor­ry you at least a lit­tle?

6 years ago

Jazz gets its nar­colep­sy up­grade drug decked out for the FDA as clock ticks down on cash cow patents

6 years ago

Deep im­pact: Drugs to watch in Q3 — PBM analy­sis

6 years ago
Pharma

On­col­o­gists lis­ten when the FDA speaks, even af­ter a drug hits the mar­ket

6 years ago

A mi­cro­cap biotech salves old wounds with pos­i­tive PhII re­port on sta­tus epilep­ti­cus, but plen­ty of ques­tions re­main

6 years ago

Take­da turns to emerg­ing mar­kets, West­ern Eu­rope in scram­ble to of­fload Shire debt — re­port

6 years ago

Enan­ta's NASH drug bare­ly meets main goal in mid-stage study

6 years ago

Af­ter rocky hep C path, Achillion finds sur­er foot­ing with FDA break­through sta­tus

6 years ago

Med­Co builds its case for star cho­les­terol RNAi ther­a­py with two new pos­i­tive piv­otal stud­ies

6 years ago

Top GSK/Vi­iV sci­en­tist who co-in­vent­ed an HIV block­buster books a trip to biotech

6 years ago
People
Pharma

FDA en­dors­es Bavar­i­an Nordic's mon­key­pox vac­cine, mark­ing world's first ap­proval

6 years ago
FDA+

Hy­po­glycemia 'Epipen' clears Phase III, hur­tles to­ward FDA de­ci­sion

6 years ago

Cerev­el plots first late-stage move as Pfiz­er drug comes through in PhII Parkin­son's tri­al

6 years ago

Uro­Gen steers to­wards its first com­mer­cial drug launch, armed with strong da­ta on lead ther­a­py

6 years ago

Bay Area biotech hauls in $62M to pay the freight on ear­ly-stage CD33/CD3 T cell en­gager

6 years ago

Em­bat­tled AM­AG braces for Oc­to­ber FDA Mak­e­na ad­com, but it need not wor­ry — an­a­lyst

6 years ago
FDA+

Is Re­gen­eron los­ing its R&D mys­tique? An­a­lyst dis­counts big biotech’s run­ner-up de­vel­op­ment strat­e­gy in an in­creas­ing­ly com­modi­tized world

6 years ago

Once tout­ed as Lyri­ca ri­val for di­a­bet­ic nerve pain, Ko­re­an biotech's plas­mid prod­uct im­plodes in PhI­II

6 years ago

FDA puts the brakes on a rare dis­ease biotech’s PhI­II as reg­u­la­tors wait for an up­date — shares crum­ble

6 years ago
FDA+

Akcea’s top 3 C-suite ex­ecs are chopped out as Io­n­is sends in an in­ter­im quar­ter­back from their bench

6 years ago

Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as Ozem­pic'

6 years ago
Pharma
First page Previous page 233234235236237238239 Next page Last page
A service from the Financial Times